Hem › Levercancer (hepatocellulärt karcinom) › Illinois › Chicago
Kliniska studier för Levercancer (hepatocellulärt karcinom) i Chicago, IL
16 studier för Levercancer (hepatocellulärt karcinom) söker deltagare vid platser i och runt Chicago (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekryterarFas 1
- Exelixis Clinical Site #26, Chicago
National Liver Cancer Screening Trial
RekryterarFas 4
- Northwestern University, Chicago
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
RekryterarFas 1/2
- Local Institution - 0107, Chicago
Defining the Ablative Dose for Y-90 TARE
RekryterarFas 2
- Northwestern University, Chicago
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
RekryterarObservationsstudie
- RUSH University Medical Center, Chicago
- University of Chicago, Chicago
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RekryterarFas 3
- Research Site, Chicago
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekryterarFas 1/2
- Lurie Children's Hospital-Chicago, Chicago
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
RekryterarFas 3
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
RekryterarFas 2
- University of Chicago Comprehensive Cancer Center, Chicago
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
RekryterarObservationsstudie
- Rush University Medical Center, Chicago
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
RekryterarFas 1/2
- Northwestern University, Chicago
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
RekryterarFas 1
- Clinical Trial Site, Chicago
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
RekryterarFas 2
- Northwestern University, Chicago
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
RekryterarFas 4
- University of Chicago Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekryterarObservationsstudie
- Massive Bio SYNERGY-AI site, Chicago
The Dragon PLC Trial (DRAGON-PLC)
Rekryterar
- Rush University Medical Center, Chicago
Levercancer (hepatocellulärt karcinom)-studier i andra städer
- Houston, TX31 studier
- New York City, NY24 studier
- Dallas, TX19 studier
- Los Angeles, CA19 studier
- Boston, MA18 studier
- Cleveland, OH18 studier
- Philadelphia, PA16 studier
- Pittsburgh, PA15 studier
- San Francisco, CA14 studier
- Orange, CA14 studier
- Jacksonville, FL14 studier
- San Antonio, TX13 studier
Andra studier i Chicago
- Icke-småcellig lungcancer61 studier
- Bröstcancer59 studier
- Cancer (alla typer)51 studier
- Metastaserande cancer45 studier
- Prostatacancer45 studier
- Lungcancer41 studier
- Övervikt41 studier
- Äggstockscancer36 studier
- Kolorektal cancer34 studier
- Stroke34 studier
- Hjärtsvikt31 studier
- Övervikt29 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.